Videos

Here are the top 5 biosimilar articles for the week of October 2, 2023.

Here are the top 5 biosimilar articles for the week of September 25, 2023.

Here are the top 5 biosimilar articles for the week of September 18, 2023.

Here are the top 5 biosimilar articles for the week of September 11, 2023.

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, explains the value of interchangeability in the adalimumab space and predicts whether interchangeable biosimilars will become leaders in adoption.

Here are the top 5 biosimilar articles for the week of September 4, 2023.

Here are the top 5 biosimilar articles for the week of August 28, 2023.

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, shares her reaction to the FDA approval of Tyruko (natalizumab-sztn), the first biosimilar approved to treat multiple sclerosis (MS).

Here are the top 5 biosimilar articles for the week of August 21, 2023.

Here are the top 5 biosimilar articles for the week of August 14, 2023.

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.

Experts review best practices around plan design that payers and plan sponsors should address as more interchangeable biosimilars potentially enter the market.

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Here are the top 5 biosimilar articles for the week of August 7, 2023.

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

Here are the top 5 biosimilar articles for the week of July 31, 2023.

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.

Here are the top 5 biosimilar articles for the week of July 24, 2023.

Jonathan Kay, MD, provides an overview of the existing FDA-approved biosimilars for adalimumab.

Kimberly C. Chen DO, MSHLM, and Maia Kayal, MD, MS, review the challenges related to biosimilars from the payer perspective and strategies payers may employ to help improve the uptake of biosimilars.

Julie Reed, MS, executive director of the Biosimilars Forum, takes a look at the 3 policy initiatives that could have the greatest ramifications for the US biosimilars industry.

Here are the top 5 biosimilar articles for the week of July 17, 2023.

Jonathan Kay, MD, discusses challenges that patients may experience related to biosimilars for inflammatory conditions.

Maia Kayal, MD, MS, and Kimberly C. Chen DO, MSHLM, discuss opportunities that biosimilars provide for inflammatory conditions from both a payer and provider perspective.

Jonathan Kay, MD, and Kimberly C. Chen DO, MSHLM, define what a biosimilar is and discuss the potential for a lower cost than the reference product.

Jonathan Kay, MD, reviews the barriers related to access to biologics such as economic barriers, health inequities, or disparities.

Maia Kayal, MD, MS, provides an overview of the biologics used in inflammatory diseases.